According to the GuruFocus All-In-One Screener, the following health care stocks have positions in gurus' portfolios.
Five gurus have positions in Anika Therapeutics Inc. (ANIK, Financial).
The biotechnology company has a market cap of $871.74 million. Its revenue grew 11.30% over the past 10 years and its earnings per share (EPS) increased 31.20%.
The stock is trading with a price-earnings (P/E) ratio of 26.34. The current stock price of $59.78 is 1.13% below its 52-week high and 43.72% above its 52-week low. Over the past decade, it has returned a gain of 193%.
In the second quarter, Ken Fisher (Trades, Portfolio) added 15.33% to his position and Joel Greenblatt (Trades, Portfolio) increased his holding by 49.25%.
Nine gurus are invested in United Therapeutics Corp. (UTHR, Financial).
The biotechnology company has a market cap of $5.22 billion. Its revenue increased 21% over the past 10 years. Its EPS witnessed a 10-year growth rate of 33.80%.
The current stock price of $120.15 is 29.28% below its 52-week high and 8.34% above its 52-week low. Over the past 10 years, it has returned a gain of 264%.
During the second quarter, Greenblatt added 1.44% to his holding and David Dreman (Trades, Portfolio) established a position in the company.
Four gurus own shares of Enzymotec Ltd. (ENZY, Financial).
The biotechnology company has a market cap of $254.69 million. The current stock price of $11.25 is 10.12% below its 52-week high and 113.46% above its 52-week low. Over the past decade, it has returned a loss of 39%.
During the third quarter, John Paulson (Trades, Portfolio) reduced his position by 0.31%.
Eight gurus hold shares of Jazz Pharmaceuticals PLC (JAZZ, Financial).
The biopharmaceutical company has a market cap of $8.56 billion. The company has grown its revenue at a rate of 25.40% over a 10-year period. The stock is trading with a P/E ratio of 21.78. The price of $142.38 is 12.93% below its 52-week high and 48.82% above its 52-week low. Over the past 10 years, it has returned a gain of 995%.
Greenblatt added 140.23% to his position during the second quarter.
Eleven gurus are shareholders of Vertex Pharmaceuticals Inc. (VRTX, Financial).
The biotechnology company has a market cap of $38.83 billion. Its revenue grew 19.20% over the past decade.Â
The stock is trading with a P/E ratio of 149.53. The price of $154.02 is 8.24% below its 52-week high and 115.53% above its 52-week low. Over the past decade, it has returned a gain of 327%.
Greenblatt established a position in the company and Fisher increased his holding by 14.06% during the second quarter. The Vanguard Health Care Fund (Trades, Portfolio) reduced its position by 10.66%.
Disclosure: I do not own any shares of any stocks mentioned in this article.
